Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H1152 is a highly selective, potent, and ATP-competitive small molecule inhibitor of Rho-kinase (ROCK), primarily inhibiting ROCKII with markedly less affinity for other kinases. It is membrane permeable and exhibits much greater specificity and potency for ROCK enzymes than earlier ROCK inhibitors such as Y27632. H1152 displays biological activities such as inhibiting stress fiber formation, promoting neurite extension, preventing fragmentation of apoptotic cells, displaying pro-erectile effects in animal models, and reducing neuropathic pain. It is widely used as a research tool for studying ROCK signaling, neuronal differentiation, and cell motility and contraction[1][2][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on H1152.